JP2005522433A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005522433A5 JP2005522433A5 JP2003565527A JP2003565527A JP2005522433A5 JP 2005522433 A5 JP2005522433 A5 JP 2005522433A5 JP 2003565527 A JP2003565527 A JP 2003565527A JP 2003565527 A JP2003565527 A JP 2003565527A JP 2005522433 A5 JP2005522433 A5 JP 2005522433A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- pharmaceutical composition
- nucleic acid
- salt
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0201584A FR2835749B1 (fr) | 2002-02-08 | 2002-02-08 | Composition pharmaceutique ameliorant le transfert de gene in vivo |
| PCT/FR2003/000407 WO2003066104A2 (fr) | 2002-02-08 | 2003-02-07 | Composition pharmaceutique ameliorant le transfert de gene in vivo |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005522433A JP2005522433A (ja) | 2005-07-28 |
| JP2005522433A5 true JP2005522433A5 (cg-RX-API-DMAC7.html) | 2006-03-16 |
| JP4613011B2 JP4613011B2 (ja) | 2011-01-12 |
Family
ID=27620039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003565527A Expired - Lifetime JP4613011B2 (ja) | 2002-02-08 | 2003-02-07 | ｉｎｖｉｖｏ遺伝子伝達を改善する医薬組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7709452B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1471944B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4613011B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE326986T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003222896A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2473212C (cg-RX-API-DMAC7.html) |
| DE (1) | DE60305443T2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2265569T3 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2835749B1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003066104A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2868953B1 (fr) * | 2004-04-16 | 2006-06-30 | Inst Nat Sante Rech Med | Composition pour le transfert intracellulaire d'un acide nucleique. |
| WO2008034123A2 (en) * | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates containing positively-charged moieties |
| DE102006051623A1 (de) | 2006-11-02 | 2008-07-31 | Horn, Peter A. | Verfahren und Stoffgemisch zur Verbesserung eines in vivo Genfransfers |
| WO2010026537A1 (en) | 2008-09-05 | 2010-03-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Novel multimodular assembly useful for intracellular delivery |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| WO2013106558A1 (en) | 2012-01-10 | 2013-07-18 | Merial Limited | Lipid based adjuvants for dna - plasmid vaccines |
| WO2013128424A1 (en) | 2012-03-02 | 2013-09-06 | Institut National De La Sante Et De La Recherche Medicale | Vaccine for prophylaxis or treatment of an allergen-driven and/or a chronic airways disease |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US20150182620A1 (en) | 2012-06-15 | 2015-07-02 | Inserm (Institut De La Sante Et De La Recherche Medicale) | Polypeptides for use in the Prophylactic Treatment of Allergic Asthma |
| PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| CA2944128C (en) | 2014-04-01 | 2022-08-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Capped and uncapped rna molecules and block copolymers for intracellular delivery of rna |
| EP3225246A1 (en) | 2016-03-31 | 2017-10-04 | Klinikum der Universität München | Synthetic compound for improving efficiency of transfection |
| US20210000917A1 (en) | 2018-03-05 | 2021-01-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and composition for the treatment of allergic asthma |
| US20220184191A1 (en) * | 2019-03-11 | 2022-06-16 | Evaxion Biotech A/S | Nucleic acid vaccination using neo-epitope encoding constructs |
| AU2021202658A1 (en) | 2021-04-28 | 2022-11-17 | Fondazione Telethon | Gene therapy |
| GB202206346D0 (en) | 2022-04-29 | 2022-06-15 | Ospedale San Raffaele Srl | Gene therapy |
| EP4704856A1 (en) | 2023-03-30 | 2026-03-11 | Vivadju | Pvax14 nucleic acid formulated with nano-vehicle in combination with all-trans retinoic acid (atra) for activating immune pathways |
| WO2024200831A1 (en) | 2023-03-30 | 2024-10-03 | Vivadju | Pvax14 nucleic acid in combination with all-trans retinoic acid (atra) and a checkpoint inhibitor for the treatment of cancer |
| WO2025129128A1 (en) | 2023-12-15 | 2025-06-19 | Vivasor, Inc. | Compositions and methods for non-viral delivery of therapeutic compounds |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5470568A (en) * | 1992-02-13 | 1995-11-28 | Arch Development Corporation | Methods and compositions of a polymer (poloxamer) for cell repair |
| GB9216082D0 (en) * | 1992-07-28 | 1992-09-09 | Univ Nottingham | Lymphatic delivery composition |
| US6221959B1 (en) * | 1994-11-18 | 2001-04-24 | Supratek Pharma, Inc. | Polynucleotide compositions |
| US5656611A (en) * | 1994-11-18 | 1997-08-12 | Supratek Pharma Inc. | Polynucleotide compositions |
| US6359054B1 (en) * | 1994-11-18 | 2002-03-19 | Supratek Pharma Inc. | Polynucleotide compositions for intramuscular administration |
| US6040295A (en) * | 1995-01-13 | 2000-03-21 | Genemedicine, Inc. | Formulated nucleic acid compositions and methods of administering the same for gene therapy |
| CA2315256A1 (en) * | 1997-12-16 | 1999-06-24 | Valentis, Inc. | Needle-free injection of formulated nucleic acid molecules |
| GB9904627D0 (en) * | 1999-03-02 | 1999-04-21 | Danbiosyst Uk | Polymer compositions for polynucleotide delivery |
| AU4898699A (en) | 1999-07-16 | 2001-02-05 | Reatech | Phosphor addition in gasification |
| AU6389000A (en) * | 1999-07-28 | 2001-02-19 | Valentis, Inc. | Sonoporation of tumors |
| WO2001060415A1 (en) * | 2000-02-18 | 2001-08-23 | The Immune Response Corporation | Methods and compositions for gene delivery |
| AU2001241958A1 (en) * | 2000-03-03 | 2001-09-17 | Valentis, Inc. | Improved poloxamer and poloxamine compositions for nucleic acid delivery |
| CA2426582A1 (en) | 2000-10-20 | 2002-08-08 | Valentis, Inc. | Gene delivery formulations and methods for treatment of ischemic conditions |
-
2002
- 2002-02-08 FR FR0201584A patent/FR2835749B1/fr not_active Expired - Lifetime
-
2003
- 2003-02-07 US US10/502,973 patent/US7709452B2/en not_active Expired - Lifetime
- 2003-02-07 AU AU2003222896A patent/AU2003222896A1/en not_active Abandoned
- 2003-02-07 DE DE60305443T patent/DE60305443T2/de not_active Expired - Lifetime
- 2003-02-07 WO PCT/FR2003/000407 patent/WO2003066104A2/fr not_active Ceased
- 2003-02-07 EP EP03718854A patent/EP1471944B1/fr not_active Expired - Lifetime
- 2003-02-07 CA CA2473212A patent/CA2473212C/fr not_active Expired - Lifetime
- 2003-02-07 AT AT03718854T patent/ATE326986T1/de not_active IP Right Cessation
- 2003-02-07 JP JP2003565527A patent/JP4613011B2/ja not_active Expired - Lifetime
- 2003-02-07 ES ES03718854T patent/ES2265569T3/es not_active Expired - Lifetime
-
2010
- 2010-03-15 US US12/659,618 patent/US8367631B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005522433A5 (cg-RX-API-DMAC7.html) | ||
| US12173284B2 (en) | Modified guide RNAs | |
| Sharma et al. | Versatility of peptide nucleic acids (PNA s): Role in chemical biology, drug discovery, and origins of life | |
| JP6767976B2 (ja) | 関節疾患の治療のためのメッセンジャーｒｎａ治療法 | |
| CN102177237B (zh) | 用于贮存和稳定生物分子的基质和介质 | |
| Di Gianvincenzo et al. | Gold nanoparticles capped with sulfate-ended ligands as anti-HIV agents | |
| CN117487776A (zh) | Casz组合物和使用方法 | |
| US20190142857A1 (en) | Methods | |
| FR2835749B1 (fr) | Composition pharmaceutique ameliorant le transfert de gene in vivo | |
| KR20130051954A (ko) | 베타-ＥＮａＣ-관련 질환을 치료하기 위한 유기 조성물 | |
| US5132207A (en) | Accelerated nucleic acid reassociation method | |
| CN117396193A (zh) | 用于递送rna的组合物和方法 | |
| WO2003101394A3 (en) | Defensins: use as antiviral agents | |
| US9492470B2 (en) | Use of HMGA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells | |
| US20240384269A1 (en) | Compositions containing nucleic acid nanoparticles and processes related to alteration of their physiochemical characteristics | |
| CN101422152B (zh) | 一种复合杀生剂 | |
| SG194626A1 (en) | A method for manufacturing pegylated oligonucleotides | |
| JP3289912B2 (ja) | ポリアミノ酸オリゴヌクレオチドキャリヤー | |
| Hollstein et al. | Inhibition of ribonucleic acid synthesis by myxin | |
| JP2012509904A (ja) | 核酸送達組成物および核酸送達法 | |
| JPH10158196A (ja) | 核酸安定化用キャリアー | |
| Poddar et al. | ZIF polymorphs for nucleic acid delivery and targeted knockdown of gene expression in prostate cancer | |
| EP3523431B1 (en) | Improvements in or relating to gene silencing | |
| WO2019144064A2 (en) | Nanoparticles comprising protein-polynucleotide complexes and for delivering protein based complexes | |
| CN121022982A (zh) | 一种尿液总dna保存液 |